

Expected R&D Milestones

Products	Expected milestones	Timing
SAR439859 (SERD)	Proof of concept study read-out in metastatic Breast Cancer	Q3 2019
Dupixent® ^{(**)(1)}	EU regulatory decision in Atopic Dermatitis in adolescent patients	Q3 2019
sutimlimab	Proof of concept study read-out in refractory Immune Thrombocytopenic Purpura	Q4 2019
Fluzone® QIV HD	U.S. regulatory decision for ≥ 65-year old age group	Q4 2019
sutimlimab	Pivotal trial read-out in Cold Agglutinin Disease	Q4 2019
Dupixent® ^{(**)(1)}	Pivotal trial read-out in Atopic Dermatitis in 6-11 years	Q4 2019
SAR440340 (Anti-IL33 mAb) ^{(**)(1)}	Proof of concept study read-out in Chronic Obstructive Pulmonary Disease	Q4 2019
dupilumab ^{(**)(1)}	EU regulatory decision in Chronic Rhinosinusitis with Nasal Polyps	Q1 2020
isatuximab	Pivotal trial read-out in 1-3L RRMM (IKEMA)	Q1 2020
olipudase alfa	Pivotal trial read-out in Acid Sphingomyelinase Deficiency	Q1 2020
isatuximab	U.S. regulatory decision in 3L Relapsed-Refractory Multiple Myeloma	Q2 2020
isatuximab	EU regulatory decision in 3L Relapsed-Refractory Multiple Myeloma	Q2 2020
MenQuadfi™	U.S. regulatory decision for > 2 year old age group	Q2 2020
Fluzone® QIV HD	EU regulatory decision for ≥ 65-years old age group	Q2 2020
avalglucosidase alfa	Pivotal trial read-out in Pompe Disease	Q2 2020